ERBB2 and non-small cell lung carcinoma: Trastuzumab monotherapy was evaluated in the phase II HOT1303-B trial, which enrolled pre-treated HER2-altered NSCLC patients and resulted in no therapeutic response (ORR 0%), although it achieved a disease control ratio (DCR) of 70.0% and a median PFS of 5.2 months [45].